Zeda Zhang
Overview
Explore the profile of Zeda Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mao N, Lee Y, Salsabeel N, Zhang Z, Li D, Kaur H, et al.
Sci Adv
. 2025 Feb;
11(6):eadq3802.
PMID: 39919177
Recent phase 3 clinical trial showed improved radiographic progression-free survival in PTEN-deficient prostate cancers treated with combined Akt and AR inhibition. Building on this and our previous research into PI3K...
2.
Lee E, Zhang Z, Chen C, Choi D, Rivera A, Linton E, et al.
bioRxiv
. 2024 Apr;
PMID: 38562884
There is optimism that cancer drug resistance can be addressed through appropriate combination therapy, but success requires understanding the growing complexity of resistance mechanisms, including the evolution and population dynamics...
3.
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson N, et al.
Cancer Cell
. 2023 Jul;
41(8):1427-1449.e12.
PMID: 37478850
Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the mutational signatures of more than...
4.
Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, et al.
Cell
. 2023 Jun;
186(13):2748-2764.e22.
PMID: 37267948
Ferroptosis, a cell death process driven by iron-dependent phospholipid peroxidation, has been implicated in various diseases. There are two major surveillance mechanisms to suppress ferroptosis: one mediated by glutathione peroxidase...
5.
Li X, Selli C, Zhou H, Cao J, Wu S, Ma R, et al.
J Exp Med
. 2023 Feb;
220(4).
PMID: 36749798
Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of...
6.
Mao N, Zhang Z, Lee Y, Choi D, Rivera A, Li D, et al.
Nat Commun
. 2021 Aug;
12(1):5053.
PMID: 34417459
Previous studies have suggested that PTEN loss is associated with p110β signaling dependency, leading to the clinical development of p110β-selective inhibitors. Here we use a panel pre-clinical models to reveal...
7.
Szeglin B, Wu C, Marco M, Park H, Zhang Z, Zhang B, et al.
Cancer Rep (Hoboken)
. 2021 Jun;
5(1):e1423.
PMID: 34114372
Background: Colorectal cancer is the second-leading cause of cancer-related mortality in the United States and a leading cause of cancer-related mortality worldwide. Loss of SMAD4, a critical tumor suppressor and...
8.
Adams E, Karthaus W, Hoover E, Liu D, Gruet A, Zhang Z, et al.
Nature
. 2020 Sep;
585(7826):E20.
PMID: 32895534
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Zhang Z, Karthaus W, Lee Y, Gao V, Wu C, Russo J, et al.
Cancer Cell
. 2020 Jul;
38(2):279-296.e9.
PMID: 32679108
Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance...
10.
Zhang Z, Zhou C, Li X, Barnes S, Deng S, Hoover E, et al.
Cancer Cell
. 2020 Mar;
37(4):584-598.e11.
PMID: 32220301
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss as a cause of antiandrogen...